OBJECTIVE To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy groups impact patients' willingness to try a biosimilar. METHODS An international surv...

We appreciate Meacci et al for the comments on the anti-drug antibody (ADA) detection methods. As noted by Meacci et al, the Meso Scale Discovery (MSD) electrochemiluminescence (ECL) bridging assay (Maryland, USA) was used in the SB4 Phase III study to detect ADAs. The bridging assay format relies on the characteristics of ADA to crosslink two drug molecules conjugated to a capture and a detect...

INTRODUCTION To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy for patients, a systematic literature review was conducted of all switching studies between related biologics (including biosimilars). METHODS A systematic search was cond...